Domain and Rusnano sign $760m US-Russian healthcare investment tie-up
This article was originally published in Scrip
Domain Associates, one of the largest US venture capital firms operating in the healthcare sector, and Rusnano, the Russian state-owned investor in high-tech industries, have come together in an investment partnership focused on US innovation and Russian manufacturing. The firms have agreed to invest about $760 million from their venture capital funds in about 20 US-based healthcare technology companies and in building a pharmaceutical and medical device manufacturing facility in Russia.
You may also be interested in...
Previewing the year to come, our journalists contacted more than 80 industry executives and experts for their views on what 2020 could hold for the biopharma sector. A series of articles based on these discussions were published by In Vivo’s sister publication Scrip. The following are highlights of the key issues that are top of mind for industry leaders this year, including digital tools, advanced therapies, the US election and manufacturing.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
The US election will intensify the spotlight on drug costs, regulators will have their hands full with advanced therapy filings, and the need to address rising infectious disease threats will mount. Biosimilars, cannabis and Brexit are among other hot topics for 2020.